Quantum Biopharma (QNTM) Long-Term Deferred Tax (2019 - 2025)

Quantum Biopharma (QNTM) has 7 years of Long-Term Deferred Tax data on file, last reported at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax fell 89.69% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (down 89.69% YoY), and the FY2025 full-year result was $1.2 million, down 89.69% from the prior year.
• Long-Term Deferred Tax fell to $1.2 million in Q4 2025, from $10.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $101.9 million in Q4 2023 to a low of $1.2 million in Q4 2025.
• A 5-year average of $44.3 million and a median of $43.6 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 106.11% in 2021 and sank 89.69% in 2025, its largest moves.
• Tracing QNTM's Long-Term Deferred Tax over 5 years: stood at $77.3 million in 2021, then grew by 16.94% to $90.4 million in 2022, then rose by 12.7% to $101.9 million in 2023, then sank by 88.17% to $12.1 million in 2024, then slumped by 89.69% to $1.2 million in 2025.
• Business Quant data shows QNTM's Long-Term Deferred Tax at $1.2 million in Q4 2025, $10.3 million in Q1 2025, and $12.1 million in Q4 2024.